SOURCE: Gene Express, Inc.

December 19, 2007 09:00 ET

Gene Express Appoints David Johnston, Ph.D. to Its Scientific Advisory Board

TOLEDO, OH--(Marketwire - December 19, 2007) - Gene Express, Inc. today announced that it has appointed David Johnston, Ph.D. to its Scientific Advisory Board. Dr. Johnston will be joining Dr. David Sidransky, M.D. and Michael N. Liebman, Ph.D., as previously announced on November 29, to form this prestigious team of internationally recognized experts.

Gerald Vardzel, CEO of Gene Express, commented, "With the addition of Dr. Johnston, and the continued contribution of Drs. Sidransky and Liebman, we have secured the involvement of distinguished advisors who bring a broad understanding of molecular diagnostics as well as deep experience advising biotechnology and pharmaceutical companies at various stages of growth. We are privileged to have this accomplished group of scientific and clinical thought leaders join our Scientific Advisory Board."

David M. Johnston, Ph.D., is Vice President and the Chief Scientific Officer for Esoterix Clinical Trials Services (Esoterix), the clinical trials division of LabCorp. Esoterix provides specialized and routine laboratory analyses for pharmaceutical and diagnostic product development worldwide. Dr. Johnston earned his Ph.D. in Microbiology and Immunology from the University of North Carolina at Chapel Hill School of Medicine and has been involved in clinical research for more than 15 years. Dr. Johnston studied gene regulation and surface virulence determinants in the pathogenic Neisseriae. He later studied drug resistance in HIV and worked on the first clinical diagnostic assays to detect HIV drug resistance mutations. Previously, Dr. Johnston held leadership positions in Research and Development and clinical trials Quality Assurance at LabCorp. Dr. Johnston participated in the DIA workshops on pharmacogenomics data submissions and served on the AACC Advisory Committee on pharmacogenomic assay validation. Dr. Johnston is an adjunct professor in the clinical research department of the Campbell University School of Pharmacy, and serves on the scientific advisory board for Kylin Therapeutics. He is a member of the American Association for the Advancement of Science, the Drug Information Association, American Association for Clinical Chemistry, and American Society for Microbiology.

Dr. Johnston stated, "I am pleased to join Gene Express' Scientific Advisory Board. I look forward to contributing to strategies that accelerate drug discovery and biomarker development to further precision medicine."

About Gene Express, Inc.

Gene Express, Inc. accelerates and enables drug and molecular diagnostic development by providing standardized genomic data. The Company's proprietary and patented StaRT-PCR™ (Standardized Reverse Transcription Polymerase Chain Reaction) platform technology for measuring gene expression levels in cells, clinical biopsies and blood is being used by numerous pharmaceutical concerns, as well as leading academic centers. The Company's $3 billion focus market for licensing and contract services includes the drug development, academic and molecular diagnostics segments. Additional information is available on the Company's website at www.geneexpressinc.com.

Any forecasts, plans, projections and other information contained in this press release describing events or results that may occur in the future are "forward-looking statements" as defined in the United States Private Securities litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and important factors that are beyond the control of the Company that could cause actual results and events to differ materially from the results presently anticipated or projected. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to this cautionary statement. All forward-looking statements contained herein speak only as of the date of this release and are based on current expectations. The Company disclaims any obligation to update or revise any forward-looking statements.

Contact Information